Immunovant (IMVT) Other financing activities (2019 - 2026)

Immunovant's Other financing activities history runs 8 years deep, the most recent figure standing at $3.6 million for Q1 2026.

• Quarterly Other financing activities rose 282.17% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.1 million (up 982.23% YoY) and the FY2026 annual result came in at $52.1 million, up 982.23% from the prior year.
• Other financing activities was $3.6 million for Q1 2026 at Immunovant, down from $21.0 million in the prior quarter.
• Across five years, Other financing activities topped out at $24.6 million in Q3 2025 and bottomed at $21000.0 in Q2 2022.
• A 5-year average of $4.0 million and a median of $910500.0 in 2023 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2022 — Other financing activities tumbled 83.09% — and 2023, when it jumped 4138.1%.
• Immunovant's Other financing activities stood at $403000.0 in 2022, then surged by 671.96% to $3.1 million in 2023, then dropped by 20.8% to $2.5 million in 2024, then jumped by 752.07% to $21.0 million in 2025, then tumbled by 83.05% to $3.6 million in 2026.
• Business Quant data shows IMVT's Other financing activities at $3.6 million in Q1 2026, $21.0 million in Q4 2025, and $24.6 million in Q3 2025.